8-K: Xeris Biopharma Exceeds 2024 Revenue Guidance, Anticipates Positive Cash Flow

Xeris Biopharma expects to surpass its full-year 2024 revenue guidance, reaching $203 million and anticipates a year-end cash position of over $71 million with positive cash flow in the fourth quarter.

Summary

• Xeris Biopharma anticipates full-year 2024 revenue of $203 million, exceeding the previous guidance of $198-$202 million.
• The company expects to end 2024 with over $71 million in cash, cash equivalents, and short-term investments.
• Xeris generated positive cash flow in the fourth quarter of 2024.
• Fourth-quarter revenue is projected to be $60 million, representing a 35% increase compared to the same period last year.
• Full-year revenue growth is estimated at 24% compared to the previous year.
• Recorlev net revenue is expected to increase by approximately $5 million or 28% sequentially in Q4 2024.
• A $3 million milestone payment was received from Beta Bionics for a glucagon formulation.
• Amgen terminated its license agreement with Xeris, but this is not expected to have a material impact on Xeris' outlook.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to exceeding revenue guidance, strong cash position, and positive cash flow. The termination of the Amgen agreement is a minor negative, but the overall tone is optimistic.

Positives

• Xeris exceeded its full-year 2024 revenue guidance, indicating strong sales performance.
• The company's cash position is strong, with over $71 million expected at year-end.
• Xeris achieved positive cash flow in the fourth quarter, demonstrating improved financial health.
• Recorlev achieved a record number of new starts and referrals.
• Gvoke maintained a strong market share of approximately 35%.
• The milestone payment from Beta Bionics highlights successful partnerships and technology development.

Negatives

• Amgen terminated its exclusive worldwide license agreement with Xeris, although it is not expected to have a material impact.

Risks

• The company's financial position and need for financing could impact its product development and commercialization efforts.
• Market acceptance of Xeris' products in a competitive environment is a risk.
• Reliance on third-party suppliers, including single-source suppliers, poses a risk to the supply chain.
• The company relies on third parties to conduct clinical trials, which could introduce delays or other issues.
• The ability of Xeris' product candidates to compete successfully with existing and new drugs is a risk.
• Protecting intellectual property and proprietary technology is crucial for the company's success.

Future Outlook

Xeris is focused on driving product revenue growth and advancing its pipeline, particularly the Phase 3-ready XP-8121 program, and anticipates a transformational 2025.

Management Comments

• John Shannon, CEO of Xeris, stated that the impressive results are driven by accelerating demand for Recorlev and continued strong Gvoke demand.
• The CEO also mentioned that the company is well positioned for a transformational 2025 with its commercial engine and strong balance sheet.

Industry Context

This announcement indicates strong performance in the biopharmaceutical sector, particularly in the areas of endocrinology and metabolic disorders. The company's focus on innovative drug delivery platforms like XeriSol and XeriJect positions it well for future growth.

Comparison to Industry Standards

• Xeris' revenue growth of 24% year-over-year is strong compared to the average growth rate in the biopharmaceutical industry, which varies but is often in the single to low double-digit percentages.
• The positive cash flow in Q4 is a positive sign, as many biotech companies struggle to achieve profitability, especially at this stage of development.
• The 35% market share for Gvoke is a strong indicator of product adoption and market penetration, which is comparable to other successful specialty pharmaceutical products.
• The milestone payment from Beta Bionics is a positive sign of successful partnerships and technology development, which is a key factor for growth in the biotech industry.
• While the termination of the Amgen license agreement is a setback, the fact that it is not expected to have a material impact on Xeris' outlook suggests that the company has a diversified portfolio and is not overly reliant on any single partnership.

Stakeholder Impact

• Shareholders will likely react positively to the news of exceeding revenue guidance and positive cash flow.
• Employees may feel more secure due to the company's improved financial health.
• Customers will continue to benefit from Xeris' products.
• Suppliers may see increased business opportunities with Xeris.
• Creditors may view Xeris as a lower-risk borrower due to its improved financial performance.

Next Steps

• The company will release its full 2024 financial results and 2025 outlook on March 6, 2025.
• Xeris will continue to focus on driving product revenue growth and advancing its pipeline, particularly the XP-8121 program.

Key Dates

Keywords

Xeris Biopharma, Revenue, Financial Results, Recorlev, Gvoke, Cash Flow, Biopharmaceutical, XeriSol, XeriJect, Hypoglycemia, Cushings Syndrome, Hypothyroidism